ライフサイエンスコーパス: dipeptidyl

1 Dipeptidyl (acyloxy)methyl ketones (AOMKs) were function

2 and parasite-selective delivery of a potent dipeptidyl aminopeptidase inhibitor.

3 The proline-specific dipeptidyl aminopeptidase IV (DPP IV, DPP-4, CD26), wide

4 Cathepsin C (CatC) is a cysteine dipeptidyl aminopeptidase that activates most of tissue-

5 In particular, for dipeptidyl aminopeptidase, an SP that is recognized by t

6 Dipeptidyl aminopeptidase-like protein 6 (DPP6) was firs

7 d Kv channel-interacting protein (KChIP) and dipeptidyl aminopeptidase-like protein subunits comprise

8 2,6-Dipeptidyl-anthraquinones are a promising class of nucle

9 the proteasomal inhibition mechanism of the dipeptidyl boronate N-(4-morpholine)carbonyl-beta-(1-nap

10 e pH-dependent cyclization prevalent in most dipeptidyl boronic acids that attenuates their potency a

11 hesis can occur in vivo through nonenzymatic dipeptidyl cyclization and presents a remarkably clean e

12 of a diastereomeric pair of N-Fmoc-protected dipeptidyl diazoketones.

13 (EGFP)-marked HBC-3 cells into wild-type or dipeptidyl dipeptidase IV (DPPIV) knockout blastocysts.

14 n T2, before generating the l-Phe-l-Ser-S-T2 dipeptidyl enzyme intermediate.

15 We describe herein the optimization of dipeptidyl inhibitors of norovirus 3C-like protease usin

16 The dipeptidyl peptidase (DPP) 4 family includes four enzyme

17 The intracellular peptidases dipeptidyl peptidase (DPP) 8 and DPP9 are involved in mu

18 Dipeptidyl peptidase (DPP)-4 inhibition is a glucose-low

19 The binding kinetics and thermodynamics of dipeptidyl peptidase (DPP)-4 inhibitors (gliptins) were

20 Dipeptidyl peptidase (DPP)-IV inhibitory peptides were p

21 (INS1007) is an oral reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), an enzyme responsible fo

22 tudies, CTL generated from mice deficient in dipeptidyl peptidase 1 (DPP1) were used to investigate t

23 We found that the cellular peptidases dipeptidyl peptidase 3 (DPP-3) and thimet oligopeptidase

24 Dipeptidyl peptidase 3 (DPP3) is a zinc-dependent hydrol

25 ke WTX, PALB2, and SQSTM1, we found that the dipeptidyl peptidase 3 (DPP3) protein binds KEAP1 via an

26 as a mediator of the therapeutic effects of dipeptidyl peptidase 4 (DPP-4) inhibition (vildagliptin)

27 n), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excelle

28 perglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.

29 antidiabetic incretin-based drugs, including dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-l

30 rior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have inclu

31 on-like peptide 1 receptor (GLP-1) agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, peroxisome pr

32 outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo

33 omaltase, glucose transporter 2 (GLUT2), and dipeptidyl peptidase 4 (DPP-4), as well as that of the p

34 Previous analysis of mice lacking the enzyme dipeptidyl peptidase 4 (DPP4(-/-) mice), a biomedically

35 ted proteins such as the tetraspanin CD9 and dipeptidyl peptidase 4 (DPP4) along with multiple endoso

36 due to reduced levels of the virus receptor, dipeptidyl peptidase 4 (DPP4) and higher basal levels of

37 ory syndrome coronavirus (MERS-CoV) utilizes dipeptidyl peptidase 4 (DPP4) as an entry receptor.

38 r (Gipr)-deficient mice receiving background dipeptidyl peptidase 4 (DPP4) inhibitor treatment were c

39 like peptide 1 receptor (GLP1R) agonists and dipeptidyl peptidase 4 (DPP4) inhibitors, can also reduc

40 like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase 4 (DPP4) inhibitors, with the risk

41 However, whether increased dipeptidyl peptidase 4 (DPP4) is involved in the pathoge

42 Dipeptidyl peptidase 4 (DPP4) is the receptor for cell b

43 MERS-CoV to the cell surface entry receptor dipeptidyl peptidase 4 (DPP4) occurs via S1(B) We now de

44 th Jamaican fruit bat (Artibeus jamaicensis) dipeptidyl peptidase 4 (DPP4) receptor and MERS-CoV repl

45 avirus (MERS-CoV) binds to cellular receptor dipeptidyl peptidase 4 (DPP4) via the spike (S) protein

46 Recently, the MERS-CoV receptor dipeptidyl peptidase 4 (DPP4) was identified and the spe

47 ions with the MERS-CoV cell surface receptor dipeptidyl peptidase 4 (DPP4), and evolutionary mechanis

48 receptor for MERS-CoV has been identified as dipeptidyl peptidase 4 (DPP4), the mouse DPP4 homologue

49 Taken together, our results point toward dipeptidyl peptidase 4 (DPP4)-dependent endosomal uptake

50 binding of the RBD to its cellular receptor, dipeptidyl peptidase 4 (DPP4).

51 , 4, 5, 13, and 14; sucrase isomaltase (SI); dipeptidyl peptidase 4 (Dpp4); glucose transporter type

52 Dipeptidyl peptidase 4 (DPP4, CD26) is a protease that c

53 Dipeptidyl peptidase 4 (DPP4, CD26), a type II transmemb

54 hree different epitopes in the RBD and human dipeptidyl peptidase 4 (hDPP4) interface with subnanomol

55 V after adenovirus transduction of the human dipeptidyl peptidase 4 (hDPP4) receptor and then analyze

56 omozygous (+/+) and heterozygous (+/-) human dipeptidyl peptidase 4 (hDPP4) transgenic mice to study

57 Human dipeptidyl peptidase 4 (hDPP4) was recently identified a

58 etformin (sulfonylureas, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4] inhibitors, glucagon-like

59 ike peptide 1 [GLP-1] analogue) or enhancer (dipeptidyl peptidase 4 [DPP4] inhibitor).

60 t cells were identified as a major source of dipeptidyl peptidase 4 and we also found that skin mast

61 We further show dipeptidyl peptidase 4 expression, MERS-CoV replication,

62 Previous trial results have suggested that dipeptidyl peptidase 4 inhibitor (DPP4i) use might incre

63 ficacy of two clinically used T2D drugs: the dipeptidyl peptidase 4 inhibitor linagliptin and the sul

64 rdiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patie

65 5%) while taking metformin with or without a dipeptidyl peptidase 4 inhibitor.

66 ascular safety of alogliptin, a nonselective dipeptidyl peptidase 4 inhibitor.

67 Dipeptidyl peptidase 4 inhibitors had an increased risk

68 gh biguanides, sulfonylurea, glitazones, and dipeptidyl peptidase 4 inhibitors have variable effects

69 ingestion and is critical for the actions of dipeptidyl peptidase 4 inhibitors that enhance GLP-1 lev

70 ike peptide 1 mimetics, amylin mimetics, and dipeptidyl peptidase 4 inhibitors), in addition to diet

71 nd 330) that match the human sequence in the dipeptidyl peptidase 4 receptor, making mice susceptible

72 MERS-CoV antigen; double immunostaining with dipeptidyl peptidase 4 showed colocalization in scattere

73 evaluated their efficacy and safety in human dipeptidyl peptidase 4 transgenic (hDPP4 Tg+) mice.

74 Dipeptidyl peptidase 4 was found to be expressed in mast

75 der enzymes (lactase, sucrase-isomaltase and dipeptidyl peptidase 4) and visible subepithelial and sm

76 ss spectrometry analysis revealed that DPP4 (dipeptidyl peptidase 4) was selectively expressed on the

77 corresponding oxopeptides toward cleavage by dipeptidyl peptidase 4, the principal regulator of their

78 lmonary expression of the MERS-CoV receptor, dipeptidyl peptidase 4, was similar in marmosets and mac

79 ns, the neural cell adhesion molecule L1 and dipeptidyl peptidase 4, were further studied.

80 of incretin mimetic drugs and inhibitors of dipeptidyl peptidase 4, which degrades GLP-1.

81 Trials of inhibitors of dipeptidyl peptidase 4, which enhance the effect of endo

82 romal cell-derived factor-1-degrading enzyme dipeptidyl peptidase 4.

83 tors expressing the human host-cell receptor dipeptidyl peptidase 4.

84 itute or an inhibitor of the serine protease dipeptidyl peptidase 4.

85 cludens-1, mucins-1 and -2, antigen A33, and dipeptidyl peptidase 4.

86 stasis: neural cell adhesion molecule L1 and dipeptidyl peptidase 4.

87 nel subunit Kv4.2 with its auxiliary subunit dipeptidyl peptidase 6 (DPP6), and thereby modulates neu

88 racting proteins (KChIPs) and transmembrane, dipeptidyl peptidase 6 and 10 (DPP6/10) accessory subuni

89 including dipeptidyl peptidase IV (DPP IV), dipeptidyl peptidase 8 (DPP8), fibroblast activation pro

90 Here we identified the cytosolic dipeptidyl peptidase 9 (DPP9) as a SUMO1 interacting pro

91 3.98 x 10(-12)) within the gene that encodes dipeptidyl peptidase 9 (DPP9); and on chromosome 21q22.1

92 es inflammasome activation in the context of dipeptidyl peptidase 9 inhibition and could thereby incr

93 ilization, but decreases NLRP1 activation on dipeptidyl peptidase 9 inhibition.

94 lose FAP homologues dipeptidyl peptidase IV, dipeptidyl peptidase 9, and prolyl oligopeptidase.

95 demonstrate that M1184V increases binding to dipeptidyl peptidase 9, which can account for its inhibi

96 Both proteases display dipeptidyl peptidase activity, but FAP alone has endopep

97 l modification of chemokines mediated by the dipeptidyl peptidase DPP4 (CD26) has been shown to negat

98 Like the closely related dipeptidyl peptidase DPPIV, the extracellular domain of

99 rectly inhibits the activity of MMP20, KLK4, dipeptidyl peptidase I (DPPI) (an in vitro activator of

100 Dipeptidyl peptidase I (DPPI) is a cysteine aminopeptida

101 Dipeptidyl peptidase I (DPPI) is a cysteine protease req

102 Dipeptidyl peptidase I (DPPI) is a lysosomal cysteine pr

103 e injected TxA into ileal loops in PAR(2) or dipeptidyl peptidase I (DPPI) knockout mice or in wild-t

104 In this study, we show that the absence of dipeptidyl peptidase I (DPPI), a lysosomal cysteine prot

105 Cathepsin C, or dipeptidyl peptidase I, is a lysosomal cysteine protease

106 n inactivating mutation in the gene encoding dipeptidyl peptidase I, resulting in neutrophils lacking

107 aring features like propeptide processing by dipeptidyl peptidase I, storage, and release as an activ

108 ial of alpha-amylase, alpha-glucosidase, and dipeptidyl peptidase III (DPP III) enzyme activities.

109 Dipeptidyl peptidase III (DPP III) is one of the most im

110 glucagon-like peptide 1 (GLP1) mimetics and dipeptidyl peptidase inhibitors that enhance GLP1 recept

111 method to a variety of proteases, including dipeptidyl peptidase IV (DPP IV), dipeptidyl peptidase 8

112 ained lactam aminoboronic acid inhibitors of dipeptidyl peptidase IV (DPP IV; E.C. 3.4.14.5).

113 e synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of typ

114 novel aminopiperidine-fused imidazopyridine dipeptidyl peptidase IV (DPP-4) inhibitor 1 has been dev

115 ered as potent, selective, and orally active dipeptidyl peptidase IV (DPP-4) inhibitors by extensive

116 les are rapidly inactivated by the action of dipeptidyl peptidase IV (DPP-4) which limits their use a

117 Dipeptidyl peptidase IV (DPP-IV) degrades the incretin h

118 e synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of ty

119 agon-like peptide-1 (GLP-1) degrading enzyme dipeptidyl peptidase IV (DPP-IV) have been shown to be e

120 Xanthine oxidase (XO) and dipeptidyl peptidase IV (DPP-IV) inhibition by amino aci

121 ad angiotensin-I-converting enzyme (ACE) and dipeptidyl peptidase IV (DPP-IV) inhibitory activities,

122 tent angiotensin converting enzyme (ACE) and dipeptidyl peptidase IV (DPP-IV) inhibitory and oxygen r

123 Nine novel dipeptidyl peptidase IV (DPP-IV) inhibitory peptides (FL

124 ts (DOE) was used to optimise the release of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides dur

125 of 72 dietary proteins to act as a source of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides.

126 Camel milk proteins contain dipeptidyl peptidase IV (DPP-IV) inhibitory peptides.

127 as no significant effect of pH regulation on dipeptidyl peptidase IV (DPP-IV) properties.

128 These peptides are known to act as preferred dipeptidyl peptidase IV (DPP-IV) substrates.

129 HSA), other components, such as the protease dipeptidyl peptidase IV (DPP-IV), possibly contribute to

130 Dipeptidyl peptidase IV (DPP-IV; E.C. 3.4.14.5), a serin

131 Dipeptidyl peptidase IV (DPP4) deactivates glucose-regul

132 Dipeptidyl peptidase IV (DPP4) inhibitors are emerging a

133 Dipeptidyl peptidase IV (DPPIV) activity was quantified

134 epatocytes can give rise to SHPCs, rats with dipeptidyl peptidase IV (DPPIV) chimeric livers, which h

135 ine (C5-Pro-Pro) analogues was discovered as dipeptidyl peptidase IV (DPPIV) inhibitors as a potentia

136 Dipeptidyl peptidase IV (DPPIV), a cell surface serine p

137 ddresses the hypothesis that the activity of dipeptidyl peptidase IV (DPPIV), an enzyme that inactiva

138 ffects of HIR on engraftment of transplanted dipeptidyl peptidase IV (DPPIV)-positive hepatocytes in

139 rotein (FAP) is a serine protease related to dipeptidyl peptidase IV (DPPIV).

140 ed structure of AprA has similarity to human dipeptidyl peptidase IV (DPPIV).

141 y inhibition of the closely related protease dipeptidyl peptidase IV (DPPIV).

142 proteins after enzymatic digestion, against dipeptidyl peptidase IV (DPPIV); an enzyme known to deac

143 Wild-type (dipeptidyl peptidase IV [DPPIV(+)]) embryonic day (ED) 1

144 hepatocyte colonies with strong canalicular dipeptidyl peptidase IV activity.

145 tivities, among them primarily inhibition of dipeptidyl peptidase IV and angiotensin-converting enzym

146 assays based on F344 recipient rats lacking dipeptidyl peptidase IV enzyme activity to identify tran

147 ibited APCE with a K(i) of 54 microM but not dipeptidyl peptidase IV even at 2 mM.

148 vivo, but this effect was only detected with dipeptidyl peptidase IV inhibition, while mucosal respon

149 ulocyte-colony stimulating factor (G-CSF), a dipeptidyl peptidase IV inhibitor (DPP-4i), and a proton

150 in medicinal chemistry applications such as dipeptidyl peptidase IV inhibitors.

151 The highest dipeptidyl peptidase IV inhibitory activity was obtained

152 One week post-MMC treatment, dipeptidyl peptidase IV negative host rats were given a

153 vivo and mature into hepatocytes expressing dipeptidyl peptidase IV or fumarylacetoacetate hydrolase

154 ntained large clusters of sinusoids lined by dipeptidyl peptidase IV positive endothelial cells coexp

155 newborn, or adult total liver isolates from dipeptidyl peptidase IV positive rats.

156 ent on degradation by neutral endopeptidase, dipeptidyl peptidase IV, and aminopeptidase P.

157 ts but does not inhibit close FAP homologues dipeptidyl peptidase IV, dipeptidyl peptidase 9, and pro

158 Three groups of mutant F344 dipeptidyl peptidase IV-deficient (DPPIV(-)) rats were r

159 , we used transplanted cells as reporters in dipeptidyl peptidase IV-deficient mice.

160 F344 rat hepatocytes with or without DAR in dipeptidyl peptidase IV-deficient rats.

161 ter transplanting syngeneic hepatocytes into dipeptidyl peptidase IV-deficient rats.

162 t and proliferation of transplanted cells in dipeptidyl peptidase IV-deficient rats.

163 r repopulation by histochemical staining for dipeptidyl peptidase IV.

164 Conversely, DPP-4 Asp663 stabilizes dipeptidyl peptidase substrate binding and permits tight

165 marked TSS energy for both endopeptidase and dipeptidyl peptidase substrates, and structural modeling

166 Dipeptidyl peptidase type IV (DppIV) enzymes are broadly

167 Although endopeptidase, dipeptidyl peptidase, tripeptidyl peptidase, and acylami

168 Dipeptidyl peptidase-4 (CD26, DPP4) inhibitors are the m

169 Dipeptidyl peptidase-4 (DDP4) inhibitors target the enzy

170 te effects of treatment with vildagliptin on dipeptidyl peptidase-4 (DPP-4) activity, glucagon-like p

171 nes are terminated via enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4) and through renal clearan

172 Fibroblast activation protein (FAP) and dipeptidyl peptidase-4 (DPP-4) are highly homologous ser

173 (GLP-1) receptor agonists and inhibitors of dipeptidyl peptidase-4 (DPP-4) have shown pleiotropic ef

174 in this subgroup who also had baseline serum dipeptidyl peptidase-4 (DPP-4) higher than the populatio

175 od, crossover study in 24 patients with T2D, dipeptidyl peptidase-4 (DPP-4) inhibition and its glucos

176 bese mice (ob/ob), 45h was as effective as a dipeptidyl peptidase-4 (DPP-4) inhibitor at reducing pea

177 Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use

178 Linagliptin is a dipeptidyl Peptidase-4 (DPP-4) inhibitor that inhibits t

179 Dipeptidyl peptidase-4 (DPP-4) inhibitors have pleotropi

180 In this regard, dipeptidyl peptidase-4 (DPP-4) inhibitors have recently

181 acological levels of GLP-1 activity, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors increase conce

182 1 (GLP-1) secretion, on glucose lowering by dipeptidyl peptidase-4 (DPP-4) inhibitors is unclear.

183 Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent degrad

184 Recent studies concluded that dipeptidyl peptidase-4 (DPP-4) inhibitors provide glycem

185 ike peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors represent 2 di

186 etformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-gl

187 italized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating unce

188 mpared with an active comparator drug class, dipeptidyl peptidase-4 (DPP-4) inhibitors, in patients w

189 GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit

190 bute to the mechanism by which inhibitors of dipeptidyl peptidase-4 (DPP-4) lower postprandial glucos

191 on of enzymatic degradation by inhibition of dipeptidyl peptidase-4 (DPP-4) promotes glycemic reducti

192 ears to prevent apoptosis, and inhibition of dipeptidyl peptidase-4 (DPP-4), which cleaves GLP-1, is

193 GLP-1 and GLP-2 are both cleaved by dipeptidyl peptidase-4 (DPP-4); hence, inhibition of DPP

194 Aminopeptidases, such as dipeptidyl peptidase-4 (DPP-4, CD26), are potent therape

195 ulated genes, we identified the exopeptidase dipeptidyl peptidase-4 (DPP4) as a critical glucocortico

196 nfect both humans and dromedary camels using dipeptidyl peptidase-4 (DPP4) as its receptor.

197 Given the role of Dipeptidyl Peptidase-4 (DPP4) in glucose homeostasis, we

198 icyte interactions, as well as the effect of dipeptidyl peptidase-4 (DPP4) inhibitor on CD in endothe

199 The incretin-based therapies, dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon-li

200 viously disclosed azolopyrimidine containing dipeptidyl peptidase-4 (DPP4) inhibitors led us to focus

201 Dipeptidyl peptidase-4 (DPP4) inhibitors used for the tr

202 Dipeptidyl peptidase-4 (DPP4) modulates inflammation by

203 Dipeptidyl peptidase-4 (DPP4) was recently identified as

204 Cells marked by dipeptidyl peptidase-4 (DPP4)/CD26 expression are highly

205 Blocking dipeptidyl peptidase-4 activity resulted in decreased po

206 gon like peptide-1 levels and a reduction in dipeptidyl peptidase-4 activity.

207 antidiabetic agents such as sulfonylureas or dipeptidyl peptidase-4 antagonists, which promote glucos

208 We investigated whether chronic dipeptidyl peptidase-4 inhibition by sitagliptin protect

209 At 30 minutes recovery, dipeptidyl peptidase-4 inhibition mitigated the postisch

210 d-line glucose-lowering medication-including dipeptidyl peptidase-4 inhibitor (DPP4i), insulin, or th

211 dy, we compared the safety and efficacy of a dipeptidyl peptidase-4 inhibitor (sitagliptin) plus basa

212 analyses comparing empagliflozin versus the dipeptidyl peptidase-4 inhibitor class, and comparing so

213 ium-glucose cotransporter-2 inhibitor versus dipeptidyl peptidase-4 inhibitor classes also produced c

214 controlled cardiovascular safety trials, the dipeptidyl peptidase-4 inhibitor linagliptin demonstrate

215 analyses of HF and related outcomes with the dipeptidyl peptidase-4 inhibitor linagliptin versus plac

216 inhibitor dapagliflozin with and without the dipeptidyl peptidase-4 inhibitor saxagliptin, and the ef

217 adverse events for those associated with the dipeptidyl peptidase-4 inhibitor sitagliptin and the glu

218 The dipeptidyl peptidase-4 inhibitor sitagliptin, an antidia

219 The addition of dipeptidyl peptidase-4 inhibitor therapy with sitaglipti

220 creasing thiazolidinedione use and increased dipeptidyl peptidase-4 inhibitor use over time (P<0.001)

221 f newer antihyperglycemic medications in the dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-

222 o assess the effectiveness of linagliptin, a dipeptidyl peptidase-4 inhibitor, in elderly patients wi

223 gonist, versus maximum approved doses of the dipeptidyl peptidase-4 inhibitor, sitagliptin, or the th

224 itiating empagliflozin versus sitagliptin, a dipeptidyl peptidase-4 inhibitor.

225 CI 1.15-1.76; six trials), intermediate with dipeptidyl peptidase-4 inhibitors (1.25, 1.08-1.45; two

226 rsus 4.9%), sulfonylurea (8.7% versus 6.9%), dipeptidyl peptidase-4 inhibitors (10.6% versus 7.5%), S

227 n compared with thiazolidinediones (TZDs) or dipeptidyl peptidase-4 inhibitors (DPP-4is) as a third a

228 ndings from preclinical studies suggest that dipeptidyl peptidase-4 inhibitors and proton-pump inhibi

229 ials supporting the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and some glucagon-like

230 lucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used for

231 There are also concerns that dipeptidyl peptidase-4 inhibitors could cause cancer, gi

232 ncretin system, GLP-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors for 26 +/- 8 months be

233 Some but not all dipeptidyl peptidase-4 inhibitors have been associated w

234 1 analogs, alpha-glucosidase inhibitors, and dipeptidyl peptidase-4 inhibitors were associated with w

235 diones were used in 6.6% of HF patients, and dipeptidyl peptidase-4 inhibitors were used in 5.1%, wit

236 n-like peptide [GLP]-1 receptor agonists and dipeptidyl peptidase-4 inhibitors) have proven efficacy

237 t for 6-12 months and once-weekly tablets of dipeptidyl peptidase-4 inhibitors.

238 s continued taking metformin with or without dipeptidyl peptidase-4 inhibitors.

239 the glucagon-like peptide-1 mimetics and the dipeptidyl peptidase-4 inhibitors.

240 essing enzyme corin and BNP-degrading enzyme dipeptidyl peptidase-4 were reduced in HF versus normal,

241 We identified a single protein, CD26 (dipeptidyl peptidase-4).

242 otentially by producing excessive amounts of Dipeptidyl peptidase-4, a protease that is a target of d

243 s augmented by pharmacological inhibition of dipeptidyl peptidase-4.

244 cluding CD103(+) and CD11b(hi) cDCs, express dipeptidyl peptidase-4/CD26.

245 -glucosidase (37.8%), alpha-amylase (35.6%), dipeptidyl peptidase-IV (34.4%), reactive oxygen species

246 uggest a variety of bioactivities, including dipeptidyl peptidase-IV (DPP-IV) and angiotensin convert

247 wever, its rapid degradation by enzymes like dipeptidyl peptidase-IV (DPP-IV) and neutral endopeptida

248 P-1 is short because of rapid degradation by dipeptidyl peptidase-IV (DPP-IV) and renal clearance.

249 f GLP-1 is short due to rapid degradation by dipeptidyl peptidase-IV (DPP-IV) and renal clearance.

250 Dipeptidyl peptidase-IV (DPP-IV) is a serine protease in

251 P-1, due to its resistance to degradation by dipeptidyl peptidase-IV (DPP-IV).

252 ate or propionate increased DBS, enhanced by dipeptidyl peptidase-IV (DPPIV) inhibition, at the same

253 s are a good source of natural inhibitors of dipeptidyl peptidase-IV and prolyl endopeptidase and cou

254 The dipeptidyl peptidase-IV inhibitor saxagliptin (Onglyza)

255 tivities and clinical variants, for example, dipeptidyl peptidase-IV inhibitor-associated noninflamma

256 d 1-beta-fructofuranosyl nystose) are potent dipeptidyl peptidase-IV inhibitors as well as peroxisome

257 ction of several serine proteases, including dipeptidyl peptidase-IV, neutrophil elastase, matrix met

258 Protein biochemistry has identified dipeptidyl peptidase-like protein 6 (DPP6) as an auxilia

259 Dipeptidyl peptidase-like protein 6 (DPP6) is an auxilia

260 , the Ca(2+) binding proteins KChIPs and the dipeptidyl peptidase-like proteins (DPPLs) DPP6 (also kn

261 +) channel-interacting proteins (KChIPs) and dipeptidyl peptidase-like proteins (DPPLs).

262 ) channel-interacting proteins (KChIPs), and dipeptidyl peptidase-like proteins (DPPLs).

263 administration of an inhibitor of the enzyme dipeptidyl-peptidase (DPP4i), which prevents the cleavag

264 glucosyltransferase); butyrylcholinesterase; dipeptidyl-peptidase 4 (CD26, adenosine deaminase comple

265 Dipeptidyl-peptidase 4 (DPP-4) inhibitors are increasing

266 CoV spike (S) glycoprotein to sialosides and dipeptidyl-peptidase 4 (the attachment and entry recepto

267 Acarbose, the dipeptidyl-peptidase 4-inhibitor sitagliptin, the glucag

268 The dipeptidyl-peptidase 6 gene has been associated with a n

269 We report that dipeptidyl-peptidase 6 interacts with a filopodia-associ

270 Dipeptidyl-peptidase 6 is an auxiliary subunit of Kv4-me

271 We find that the hippocampal neurons lacking dipeptidyl-peptidase 6 show a sparser dendritic branchin

272 dipeptidyl-peptidase 6 therefore has an unexpected but i

273 we employ knockdown and genetic deletion of dipeptidyl-peptidase 6 to reveal its importance for the

274 n, expression of sucrase isomaltase (SI) and dipeptidyl-peptidase IV (DPP-IV), two well known intesti

275 ow cytometry and histochemical estimation of dipeptidyl-peptidase IV enzyme activity of donor cells i

276 in juvenile and senescent rats deficient in dipeptidyl-peptidase IV.

277 yeast of Blastomyces dermatitidis elaborates dipeptidyl-peptidase IVA (DppIVA), a close mimic of the

278 inally, combination of DGAT1 inhibition with dipeptidyl-peptidase-4 (DPP-4) inhibition led to further

279 Fasting adipocytokines and dipeptidyl-peptidase-4 concentrations were measured.

280 Dipeptidyl-peptidase-4 levels increased after surgery (P

281 Dipeptidyl-peptidase-IV-deficient female rats received B

282 cell-base experiments with Kv4.2 and several dipeptidyl-peptidase-like protein-6 (DPPX) plasmid const

283 metabotropic glutamate receptor 5 (mGluR5), dipeptidyl-peptidase-like protein-6 (DPPX), and gamma-am

284 mined the putative novel contribution of the dipeptidyl-peptidase-like protein-6 DPP6-S to the gamma

285 hannel interacting proteins (KChIPs) and the dipeptidyl-peptidase-like proteins (DPPLs) DPPX (DPP6) a

286 ulating the biophysical properties of Kv4.2: dipeptidyl-peptidase-like type II transmembrane proteins

287 Dipeptidyl peptidases (DP) 8 and 9 are homologous, cytop

288 Dipeptidyl peptidases (DPPs) are proteolytic enzymes tha

289 ncy and high selectivity against the related dipeptidyl peptidases (DPPs) DPPIV, DPP9, DPPII, and pro

290 demonstrate that this effect is prevented by dipeptidyl peptidases (DPPs), which cleave NPY to its sh

291 ors that are selective for FAP over both the dipeptidyl peptidases (DPPs), with which it shares exope

292 f dipeptide production processes mediated by dipeptidyl-peptidases (DPPs) should be beneficial for th

293 Cyclization of linear dipeptidyl precursors derived from nonribosomal peptide

294 tein-alpha, antiplasmin-cleaving enzyme, and dipeptidyl prolyl peptidase 5) is expressed at high leve

295 ities of three compounds possessing a common dipeptidyl residue with different warheads, i.e., an ald

296 activity and physicochemical properties of a dipeptidyl series of transition state inhibitors of noro

297 ants utilize nonenzymatic cyclization of the dipeptidyl thioester to a 2,5-diketopiperazine (DKP) to

298 release and cyclization of the NRPS-tethered dipeptidyl-thioester intermediate.

299 s are gamma-glutamylcysteine (gamma-Glu-Cys) dipeptidyl transpeptidases that catalyze the synthesis o

300 The unusual Ala(4)-Phe(5) dipeptidyl ureido linkage was formed during in vitro ass